Table 2

Change in usage trend following issuance of recall notice stratified by country (results from interrupted time series analysis)

ARB	USA		Canada		Denmark		UK
	Level change (%)	Trend change (%)	Level change (%)	Trend change (%)	Level change (%)	Trend change (%)	Level change (%)	Trend change (%)
Valsartan	−6.4^*	−0.05 (0.2)	−8.0^*	−0.2^*	−0.04 (0.04)	0.0	0.61 (0.08)	0.04 (0.03)
Azilsartan	0.0	0.0	NA				0.0	0.0
Candesartan	0.1^*	0.02^*	0.2 (0.6)	0.6^*	−0.01 (0.8)	0.03^*	−0.4 (0.001)	−0.01 (0.09)
Irbesartan	1.2^*	0.01 (0.01)	0.06 (0.7)	0.2^*	−0.01 (0.2)	0.0	−0.09 (0.004)	0.01^*
Losartan	2.9^*	−0.25^*	1.7^*	−0.3^*	0.13 (0.02)	−0.03^*	0.0	−0.05^*
Olmesartan	1.4^*	0.2^*	2.1^*	−0.4^*	NA		0.16^*	0.02^*
Telmisartan	0.5^*	0.05^*	2.9^*	0.01 (0.7)	−0.01 (0.4)	0.0	0.04^*	0.0

ARB: Angiotensin-Receptor-Blocker
*p<0.0001.